SynthesisFrontiers in neurology2022
Temporal Patterning of Neurofilament Light as a Blood-Based Biomarker for Stroke: A Systematic Review and Meta-Analysis.
Synthesis in Frontiers in neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 3 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- Blood neurofilament light chain as a predictive biomarker for functional outcome of acute ischemic stroke: a systematic review and meta-analysis.Journal of comparative effectiveness research · 2025Pooled it
- Cerebrospinal fluid and blood neurofilament light chain in Parkinson's disease and atypical parkinsonian syndromes: a systematic review and Bayesian network meta-analysis.Journal of neurology · 2025Pooled it
- Neurofilament Light Chains in Systemic Amyloidosis: A Systematic Review.International journal of molecular sciences · 2024Pooled it
- Neurofilament light chain dynamics following ischemic stroke and their modulation by transauricular vagus nerve stimulation.Scientific reports · 2026Trial
- Circulating Microglia-derived Extracellular Vesicles Predict Recovery After Rehabilitation in Stroke Survivors.Translational stroke research · 2026Trial
- From Bench to Bedside: Neurofilament Light Chain as a Biomarker in Ischemic Stroke.Current medical science · 2026Review
- Plasma neurofilament light chain is associated with clinical instability in chronic autoimmune neuropathies.Scientific reports · 2026Article
- Seric Molecular Markers Correlated with Stroke Rehabilitation Outcomes: A Narrative Review.Life (Basel, Switzerland) · 2026Review
- "Time Is Brain" - for Cell Therapies.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Neurofilament light and glial fibrillary acidic protein do not reflect neuronal or glial damage during different intracranial radiotherapy regimes: a pilot study.Frontiers in oncology · 2026Article
- Serum levels of neurofilament light chain (NfL) and glial fibrillary acid protein (GFAP) in patients with asymptomatic and symptomatic carotid artery stenosis.JVS-vascular science · 2026Article
- Longitudinal Blood-Biomarker-Based Assessment of Brain Injury in Patients Undergoing Deep Brain Stimulation and Magnetic Resonance-Guided Focused Ultrasound.Movement disorders : official journal of the Movement Disorder Society · 2026Article
- Plasma Profiles of Neuroglial Injury Biomarkers after Ischemic Stroke.Translational stroke research · 2025Observational
- Toward Precision Post-Stroke Rehabilitation Medicine: Integrating Molecular, Imaging, and Computational Biomarkers for Functional Outcome Prediction.Journal of clinical medicine · 2025Review
- Mortality within three months after nonfatal ischemic stroke treated by mechanical thrombectomy in routine care-data from the German Stroke Registry.Neurological research and practice · 2025Article
- Plasma glial fibrillary acidic protein as a biomarker of acute focal brain injury after high-intensity focused ultrasound thalamotomy.Brain communications · 2025Article
- Advances in the detection of biomarkers for ischemic stroke.Frontiers in neurology · 2025Review
- The relationship between triglyceride-glucose index and serum neurofilament light chain: Findings from NHANES 2013-2014.PloS one · 2025Article
- Emerging biomarkers in ischemic stroke.Vessel plus · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Damage to axons is a core feature of ischemic stroke and cerebrovascular disease. The burden of axonal injury is correlated with the acute clinical deficits, the underlying burden of ischemic brain injury, the prognosis of recovery, and may be a meaningful therapeutic target for brain repair. Neurofilament light chain (NfL) has been identified as a blood-based biomarker that reflects neuroaxonal damage resulting from stroke. However, the utility of NfL as a blood-based biomarker in stroke is confounded by studies examining different temporal windows and patient populations. We conducted a systematic review and meta-analysis to verify the utility of blood NfL as a diagnostic, prognostic, and monitoring stroke biomarker. Nineteen studies reporting serum/plasma NfL values for a total of 4,237 distinct patients with stroke were identified. Using available summary data from the 10 studies that employed a common immunoassay platform, we utilized random effects linear mixed modeling and weighted averages to create a phasic model of serum/plasma NfL values in distinct time periods of acute stroke. Weighted averages show that blood NfL levels vary significantly across three distinct temporal epochs of acute (0-7 days), subacute (9-90 days), and chronic (>90 days) stroke with a steep peak in the early subacute period between 14 and 21 days after stroke. Blood NfL values can function as a diagnostic biomarker in distinguishing acute ischemic stroke from transient ischemic attack as well as amongst other cerebrovascular subtypes. Release of NfL into the bloodstream after stroke follows a distinct temporal dynamic that lags several weeks behind stroke onset and reliably associates with a stroke diagnosis despite some variability based on stroke subtype and severity. Identification of these temporal dynamics and the contribution of co- existent cerebrovascular disease states can improve the value of NfL as a stroke biomarker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.